- Home
- ROIV
as 11-04-2025 3:57pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Upcoming Earnings Alert:
Get ready for potential market movements as Roivant Sciences Ltd. ROIV prepares to release earnings report on 10 Nov 2025.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 8.6B | IPO Year: | N/A |
| Target Price: | $21.06 | AVG Volume (30 days): | 8.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.73 - $20.09 | Next Earning Date: | 11-10-2025 |
| Revenue: | $23,233,000 | Revenue Growth: | -35.86% |
| Revenue Growth (this year): | -18.82% | Revenue Growth (next year): | 320.50% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & Immunovant CEO | Oct 13 '25 | Sell | $16.25 | 20,727 | $336,813.75 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 9 '25 | Sell | $16.30 | 104,940 | $1,710,522.00 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 8 '25 | Sell | $16.20 | 138,602 | $2,245,352.40 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 7 '25 | Sell | $16.15 | 355,161 | $5,735,850.15 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 6 '25 | Sell | $16.34 | 171,396 | $2,800,610.64 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 23 '25 | Sell | $14.83 | 611,000 | $9,061,130.00 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 22 '25 | Sell | $15.00 | 416,182 | $6,240,568.18 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 19 '25 | Sell | $14.95 | 683,818 | $10,223,079.10 | 1,504,959 | |
| Gline Matthew | ROIV | CEO | Sep 18 '25 | Buy | $15.07 | 3,315 | $49,957.05 | 17,287,081 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Sep 5 '25 | Sell | $12.96 | 385,816 | $5,000,175.36 | 35,508,359 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Simply Wall St.
a month ago
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades
Benzinga
a month ago
Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase
Reuters
a month ago
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings
Insider Monkey
2 months ago
Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results
Zacks
2 months ago
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise Premarket Wednesday
MT Newswires
2 months ago
Sector Update: Health Care
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.